Conflict of interest:
Gender differences in the age-stratified prevalence of risk factors in Korean ischemic stroke patients: a nationwide stroke registry-based cross-sectional study
Article first published online: 22 OCT 2013
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization
International Journal of Stroke
Volume 9, Issue 6, pages 759–765, August 2014
How to Cite
Park, T. H., Ko, Y., Lee, S. J., Lee, K. B., Lee, J., Han, M.-K., Park, J.-M., Kim, D.-E., Cho, Y.-J., Hong, K.-S., Kim, J.-T., Cho, K.-H., Kim, D.-H., Cha, J.-K., Yu, K.-H., Lee, B.-C., Yoon, B.-W., Lee, J. S., Lee, J., Gorelick, P. B. and Bae, H.-J. (2014), Gender differences in the age-stratified prevalence of risk factors in Korean ischemic stroke patients: a nationwide stroke registry-based cross-sectional study. International Journal of Stroke, 9: 759–765. doi: 10.1111/ijs.12146
K-H. Y. is involved as a member of steering committee, and/or a site investigator of multicenter clinical trials or clinical studies sponsored by Otsuka Korea, Daewoong Pharmaceutical Co. Ltd, Daichi Sankyo, Novatis Korea, and Pfizer; served as the consultant or scientific advisory boardfor BMS Korea; and received lecture honoraria from MSD Korea, AstraZeneca Korea, BMS Korea, Ostuka Korea, Pfizer Korea, and Daichi Sankyo Korea (modest).
P. B. G serves on the Steering Committee for the Bayer-sponsored ARRIVE trial, as co-Director of the Lundbeck-sponsored DIAS trial of desmoteplase in acute ischemic stroke, as a cardiovascular endpoint adjudicator for studies by Roche/Parexel, Takeda, Quintiles/AstraZenica, Shire and Forest Laboratories. Dr Gorelick serves on a speaker's bureau for BoehringerIngelheim in relation to oral anticoagulation in recurrent stroke prevention for atrial fibrillation.
H-J. B. is involved in the principal investigator, a member of steering committee, and/or a site investigator of multicenter clinical trials or clinical studies sponsored by Otsuka Korea, Bayer Korea, HandokPahrmaceutical Company, SK Chemicals, ESAI-Korea, Daewoong Pharmaceutical Co. Ltd, Daichi Sankyo, Pfizer, Sanofi-Aventis Korea, and Yuhan Corporation; served as the consultant or scientific advisory board for Bayer Korea, BoehringerIngelheim Korea, YuYu Pharmaceutical Company, and BMS Korea; and received lecture honoraria from MSD Korea, AstraZeneca Korea, BMS Korea, Novatis Korea, Ostuka Korea, Pfizer Korea, Daichi Sankyo Korea, and Handok Pharmaceutical Company (modest).
T. H. P, Y. K, S. L., K. B. L., J. L., M-K. H., D-E. K., J.-M.P, Y-J. C., K-S. H., J-T. K., K-H. C., D-H. K., J-K. C., B-C. L., B-W. Y., J. S. L., and J. L. have none.
Funding: Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).
- Issue published online: 17 JUL 2014
- Article first published online: 22 OCT 2013
- Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea. Grant Number: A102065
Fig. S1. Comparison of age and sex distribution of stroke population from the Clinical Research Center for Stroke (CRCS) and from the Health Insurance Review and Assessment Service (HIRA). In HIRA, acute ischemic stroke patients (n = 5,264) who were admitted to the ER of 201 nationwide hospitals between January 2010 and March 2010 were assessed.
Table S1. Missing rates for the observed variables in total population (n = 9,417).
Table S2. Demographic and clinical characteristics of imputed and complete case.
Table S3. Prevalence ratio heterogeneity for sex among age bands in different models with stepwise adjustments (Complete case analysis, n = 5,726).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.